Cullinan Therapeutics, Inc. (CGEM) Stock: Price, Forecast & Analyst Target
Cullinan Therapeutics, Inc. (CGEM) — MoonshotScore 51/100 (Fair band), calculated Nov 18, 2026. Price $9.07 (+0.67%), as of the Nov 19, 2026 trading session; market cap $589M.
Educational signal · not a buy or sell recommendation · How to read this
Cullinan Therapeutics, Inc. · CGEM · NASDAQ
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology and immuno-oncology therapies. Their pipeline includes a diverse range of drug candidates targeting various cancer types.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Cullinan Therapeutics (CGEM)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but weak quality, weak growth and an expensive valuation. Business Quality: Thin; Financial Safety: Sound; Valuation: Rich; Growth Durability: Fading; Momentum: Slipping.
- EPS beat 6 of the last 8 reports
- Altman Z 4.34 · Piotroski F 1
- ROE -59.1% · ROA -63.1% · current ratio 7.43 · earnings yield -30.6% · free-cash-flow yield -24.8%
Holding back: weak fundamentals, a rich price
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 50 | Fair | |
| 50 | Fair | |
| 49 | Fair | |
| 49 | Fair | |
| 51 | Fair | |
| 51 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $9.07 | |
| Change on the day | +0.67% | |
| 52-week range | $7.93 – $23.19 | |
| Market capitalisation | $589M | — |
| Price / earnings (trailing) | -4.25 | |
| Shares traded on the day | 1000.0K |
Price & events
Other perspectives
Council score for Cullinan Therapeutics (CGEM): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 16, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Cullinan Therapeutics (CGEM), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cullinan Therapeutics, Inc. (CGEM) is listed on NASDAQ. It employs 109 people and is led by Nadim Ahmed. The market values it at $589M.
What do the latest results show for Cullinan Therapeutics (CGEM)?
Short answer · as of
Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $0 | -$49M | -$0.76 (diluted) |
| Q2 FY2026 | $0 | -$54M | -$0.87 (diluted) |
| Q1 FY2026 | $0 | -$50M | -$0.84 (diluted) |
| Q4 FY2025 | $0 | -$51M | -$0.86 (diluted) |
What are the financial strengths and risks for Cullinan Therapeutics (CGEM)?
Short answer · as of
The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Altman Z 4.34 · Piotroski F 1. Trailing ratios: ROE -59.1% · ROA -63.1% · current ratio 7.43 · earnings yield -30.6% · free-cash-flow yield -24.8%.
Data-derived red flags
- Negative return on equity (-59.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Cullinan Therapeutics (CGEM)?
Short answer · as of
Current published price targets run low $27.00 · high $41.00 · consensus $34.33 · median $35.00 against a quoted price of $9.07 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Cullinan Therapeutics compare with its peers?
Short answer
Cullinan Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $58.34 Nov 19, 2026 | $119B | 85 5-pillar Nov 18, 2026 | |
| $137.78 Nov 18, 2026 | $340B | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $40.04 Nov 19, 2026 | $1.30B | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $28.06 Nov 18, 2026 | $160B | 67 5-pillar Nov 18, 2026 | |
| $18.52 Nov 19, 2026 | $1.14B | 66 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Cullinan Therapeutics (CGEM) — this page | $9.07 | $589M | 51 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $27.00 – $41.00
- Consensus target
- $34.33
- Median target
- $35.00
Consensus record · Captured .
Measured against a quoted price of $9.07 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 20
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 4
- Other transactions
- 16
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CGEM in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CGEM in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Cullinan Therapeutics (CGEM)?
- Cullinan Says Partner Submits New Drug Application for Zipalertinib Combination for Certain Form of Lung Cancer
- Cullinan Therapeutics Announces NDA Submission for Zipalertinib in First-Line NSCLC
- Cullinan Therapeutics Partner Taiho Oncology Completes NDA Submission To FDA For Zipalertinib In Combination With Platinum-Based Chemotherapy For Treatment Of NSCLC Harboring EGFR Ex20ins Mutations
Common Questions About CGEM
These answers are editorial: 1 of these 9 answers is drawn from the CGEM research dossier (written May 4, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for CGEM?
CGEM carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology and immuno-oncology therapies.
Is CGEM a good stock to buy?
Stock Expert AI does not rate CGEM buy, sell or hold. Cullinan Therapeutics, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CGEM stock price today?
The last price recorded for Cullinan Therapeutics, Inc. (CGEM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CGEM price target?
The analyst consensus price target for Cullinan Therapeutics, Inc. (CGEM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for CGEM?
Cullinan Therapeutics faces several key risks inherent to its business model as a clinical-stage biopharmaceutical company. One significant risk is the potential for clinical trial failures or setbacks, which could delay or halt the development of its drug candidates.
What are the key factors to evaluate for CGEM?
Cullinan Therapeutics, Inc. (CGEM) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. The company is headquartered in Cambridge, MA. Not financial advice.
How frequently does CGEM data refresh on this page?
CGEM's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CGEM's recent stock price performance?
Cullinan Therapeutics, Inc. (CGEM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse pipeline of oncology and immuno-oncology therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CGEM overvalued or undervalued right now?
Cullinan Therapeutics, Inc. (CGEM) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 10 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com